Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Minimum Inhibitory Concentrations of Fluoroquinolones and Pyrazinamide Susceptibility Correlate to Clinical Improvement in Multidrug-resistant Tuberculosis Patients: A Nationwide Swedish Cohort Study Over 2 Decades.

Forsman LD, Jonsson J, Wagrell C, Werngren J, Mansjö M, Wijkander M, Groenheit R, Hammar U, Giske CG, Schön T, Bruchfeld J.

Clin Infect Dis. 2019 Sep 27;69(8):1394-1402. doi: 10.1093/cid/ciy1068.

PMID:
30561569
2.

Plasma concentrations of second-line antituberculosis drugs in relation to minimum inhibitory concentrations in multidrug-resistant tuberculosis patients in China: a study protocol of a prospective observational cohort study.

Davies Forsman L, Niward K, Hu Y, Zheng R, Zheng X, Ke R, Cai W, Hong C, Li Y, Gao Y, Werngren J, Paues J, Kuhlin J, Simonsson USH, Eliasson E, Alffenaar JW, Mansjö M, Hoffner S, Xu B, Schön T, Bruchfeld J.

BMJ Open. 2018 Oct 4;8(9):e023899. doi: 10.1136/bmjopen-2018-023899.

3.

Distribution of plasma concentrations of first-line anti-TB drugs and individual MICs: a prospective cohort study in a low endemic setting.

Niward K, Davies Forsman L, Bruchfeld J, Chryssanthou E, Carlström O, Alomari T, Carlsson B, Pohanka A, Mansjö M, Jonsson Nordvall M, Johansson AG, Eliasson E, Werngren J, Paues J, Simonsson USH, Schön T.

J Antimicrob Chemother. 2018 Oct 1;73(10):2838-2845. doi: 10.1093/jac/dky268.

PMID:
30124844
4.

Multi-center evaluation of GenoType MTBDRsl line probe assay for rapid detection of pre-XDR and XDR Mycobacterium tuberculosis in China.

Gao Y, Zhang Z, Deng J, Mansjö M, Ning Z, Li Y, Li X, Hu Y, Hoffner S, Xu B.

J Infect. 2018 Oct;77(4):328-334. doi: 10.1016/j.jinf.2018.06.014. Epub 2018 Jun 30.

PMID:
29969597
5.

Cross-border outbreak of extensively drug-resistant tuberculosis linked to a university in Romania.

Popovici O, Monk P, Chemtob D, Chiotan D, Freidlin PJ, Groenheit R, Haanperä M, Homorodean D, Mansjö M, Robinson E, Rorman E, Smith G, Soini H, Van Der Werf MJ.

Epidemiol Infect. 2018 May;146(7):824-831. doi: 10.1017/S095026881800047X.

PMID:
29769160
6.

The Epidemiological Significance and Temporal Stability of Mycobacterial Interspersed Repetitive Units-Variable Number of Tandem Repeats-Based Method Applied to Mycobacterium tuberculosis in China.

Li Y, Hu Y, Mansjö M, Zhao Q, Jiang W, Ghebremichael S, Hoffner S, Xu B.

Int J Environ Res Public Health. 2018 Apr 17;15(4). pii: E782. doi: 10.3390/ijerph15040782.

7.

Genetic sequencing for surveillance of drug resistance in tuberculosis in highly endemic countries: a multi-country population-based surveillance study.

Zignol M, Cabibbe AM, Dean AS, Glaziou P, Alikhanova N, Ama C, Andres S, Barbova A, Borbe-Reyes A, Chin DP, Cirillo DM, Colvin C, Dadu A, Dreyer A, Driesen M, Gilpin C, Hasan R, Hasan Z, Hoffner S, Hussain A, Ismail N, Kamal SMM, Khanzada FM, Kimerling M, Kohl TA, Mansjö M, Miotto P, Mukadi YD, Mvusi L, Niemann S, Omar SV, Rigouts L, Schito M, Sela I, Seyfaddinova M, Skenders G, Skrahina A, Tahseen S, Wells WA, Zhurilo A, Weyer K, Floyd K, Raviglione MC.

Lancet Infect Dis. 2018 Jun;18(6):675-683. doi: 10.1016/S1473-3099(18)30073-2. Epub 2018 Mar 21. Erratum in: Lancet Infect Dis. 2018 Mar 27;:.

8.

Reduced susceptibility of clinical strains of Mycobacterium tuberculosis to reactive nitrogen species promotes survival in activated macrophages.

Idh J, Andersson B, Lerm M, Raffetseder J, Eklund D, Woksepp H, Werngren J, Mansjö M, Sundqvist T, Stendahl O, Schön T.

PLoS One. 2017 Jul 13;12(7):e0181221. doi: 10.1371/journal.pone.0181221. eCollection 2017.

9.

Characterization of pyrazinamide resistance in consecutive multidrug-resistant mycobacterium tuberculosis isolates in sweden between 2003 and 2015.

Mansjo M, Werngren J, Hoffner S.

Int J Mycobacteriol. 2017 Apr-Jun;6(2):156-161. doi: 10.4103/ijmy.ijmy_23_17.

10.

Non-pncA Gene-Mutated but Pyrazinamide-Resistant Mycobacterium tuberculosis: Why Is That?

Werngren J, Alm E, Mansjö M.

J Clin Microbiol. 2017 Jun;55(6):1920-1927. doi: 10.1128/JCM.02532-16. Epub 2017 Apr 12.

11.

New insights into the mechanism of action of pyrazinamide, implications for susceptibility testing, and future regimens.

Anthony RM, den Hertog A, Mansjö M, Werngren J.

Int J Mycobacteriol. 2016 Dec;5 Suppl 1:S71-S72. doi: 10.1016/j.ijmyco.2016.08.009. Epub 2016 Sep 20.

12.

Population-based resistance of Mycobacterium tuberculosis isolates to pyrazinamide and fluoroquinolones: results from a multicountry surveillance project.

Zignol M, Dean AS, Alikhanova N, Andres S, Cabibbe AM, Cirillo DM, Dadu A, Dreyer A, Driesen M, Gilpin C, Hasan R, Hasan Z, Hoffner S, Husain A, Hussain A, Ismail N, Kamal M, Mansjö M, Mvusi L, Niemann S, Omar SV, Qadeer E, Rigouts L, Ruesch-Gerdes S, Schito M, Seyfaddinova M, Skrahina A, Tahseen S, Wells WA, Mukadi YD, Kimerling M, Floyd K, Weyer K, Raviglione MC.

Lancet Infect Dis. 2016 Oct;16(10):1185-1192. doi: 10.1016/S1473-3099(16)30190-6. Epub 2016 Jul 7.

13.

Multicenter Study of the Emergence and Genetic Characteristics of Pyrazinamide-Resistant Tuberculosis in China.

Li D, Hu Y, Werngren J, Mansjö M, Zheng X, Drobniewski F, Hoffner S, Xu B.

Antimicrob Agents Chemother. 2016 Aug 22;60(9):5159-66. doi: 10.1128/AAC.02687-15. Print 2016 Sep.

14.

Determination of MIC Breakpoints for Second-Line Drugs Associated with Clinical Outcomes in Multidrug-Resistant Tuberculosis Treatment in China.

Zheng X, Zheng R, Hu Y, Werngren J, Forsman LD, Mansjö M, Xu B, Hoffner S.

Antimicrob Agents Chemother. 2016 Jul 22;60(8):4786-92. doi: 10.1128/AAC.03008-15. Print 2016 Aug.

15.

An association study of NRAMP1, VDR, MBL and their interaction with the susceptibility to tuberculosis in a Chinese population.

Wu L, Deng H, Zheng Y, Mansjö M, Zheng X, Hu Y, Xu B.

Int J Infect Dis. 2015 Sep;38:129-35. doi: 10.1016/j.ijid.2015.08.003. Epub 2015 Aug 7.

16.

Diagnostic Performance of the New Version (v2.0) of GenoType MTBDRsl Assay for Detection of Resistance to Fluoroquinolones and Second-Line Injectable Drugs: a Multicenter Study.

Tagliani E, Cabibbe AM, Miotto P, Borroni E, Toro JC, Mansjö M, Hoffner S, Hillemann D, Zalutskaya A, Skrahina A, Cirillo DM.

J Clin Microbiol. 2015 Sep;53(9):2961-9. doi: 10.1128/JCM.01257-15. Epub 2015 Jul 15.

17.

Mycobacterium tuberculosis pyrazinamide resistance determinants: a multicenter study.

Miotto P, Cabibbe AM, Feuerriegel S, Casali N, Drobniewski F, Rodionova Y, Bakonyte D, Stakenas P, Pimkina E, Augustynowicz-Kopeć E, Degano M, Ambrosi A, Hoffner S, Mansjö M, Werngren J, Rüsch-Gerdes S, Niemann S, Cirillo DM.

mBio. 2014 Oct 21;5(5):e01819-14. doi: 10.1128/mBio.01819-14.

18.

Supplemental Content

Loading ...
Support Center